Evaluation of Relevance between Advanced Glycation End Products and Diabetic Retinopathy Stages Using Skin Autofluorescence

Yuji Takayanagi 1, Mikihiro Yamanaka 2, Jo Fujihara 3, Yotaro Matsuoka 3, Yuko Gohto 4, Akira Obana 4* and Masaki Tanito 1,∗

1 Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo 693-8501, Japan; y.takayanagi1008@med.shimane-u.ac.jp
2 Laboratory of Food and Regulation Biology, School of Agriculture, Tokai University, Kumamoto 862-8652, Japan; yamanaka.mikihiro@tsc.u-tokai.ac.jp
3 Division of Ophthalmology, Matsue Red Cross Hospital, Matsue 690-8506, Japan; aoiroelephant@hotmail.co.jp (J.F.); ymatsu@med.shimane-u.ac.jp (Y.M.)
4 Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu 430-8558, Japan; yukogo@sis.seirei.or.jp (Y.G.); obana@sis.seirei.or.jp (A.O.)

* Correspondence: tanito-oph@umin.ac.jp; Tel.: +81-853-20-2284

Received: 4 September 2020; Accepted: 4 November 2020; Published: 9 November 2020

Abstract: Advanced glycation end products (AGEs) are thought to play important roles in the pathogenesis of diabetic microangiopathy, particularly in the progression of diabetic retinopathy (DR). We assessed the levels of skin autofluorescence (sAF) to assess the association between AGEs and DR stages. A total of 394 eyes of 394 Japanese subjects (172 men, 222 women; mean age ± standard deviation [SD], 68.4 ± 13.7 years) comprised the study population, i.e., subjects with diabetes mellitus (DM) (n = 229) and non-diabetic controls (n = 165). The patients with DM were divided into those without DR (NDR, n = 101) and DR (n = 128). DR included simple (SDR, n = 36), pre-proliferative (PPDR, n = 25), and PDR (n = 67). Compared to controls (0.52 ± 0.12), the AGE scores were significantly higher in patients with DM (0.59 ± 0.17, p < 0.0001), NDR (0.58 ± 0.16, p = 0.0012), and DR (0.60 ± 0.18, p < 0.0001). The proportion of patients with PDR was significantly higher in the highest quartile of AGE scores than the other quartiles (p < 0.0001). Compared to those without PDR (SDR and PPDR), those with PDR were younger (p = 0.0006), more were pseudophakic (p < 0.0001), had worse visual acuity (VA) (p < 0.0001), had higher intraocular pressure (IOP) (p < 0.0001), and had higher AGE scores (p = 0.0016). Multivariate models also suggested that younger age, male gender, pseudophakia, worse VA, higher IOP, and higher AGE scores were risk factors for PDR. The results suggested that AGE scores were higher in patients with DM and were independently associated with progression of DR. In addition, more PDR was seen in the highest quartile of AGE scores. This study highlights the clinical use of the AGE score as a non-invasive, reliable marker to identity patients at risk of sight-threatening DR.

Keywords: advanced glycation end products (AGEs); skin autofluorescence (sAF); AGEs Sensor; diabetic retinopathy; proliferative diabetic retinopathy; neovascular glaucoma; oxidative stress

1. Introduction

Diabetic retinopathy (DR), which is a major vascular complication of diabetes mellitus (DM), has been recognized for decades, and disease progression often results in devastating visual loss [1]. Although several previous studies have shown that hyperglycemia, smoking, hypertension, and other factors are related closely to diabetic angiopathy [2–5], these traditional factors do not fully explain
the development of the vascular complications of DM and the involvement of other factors likely to promote this process.

The accumulation of advanced glycation end products (AGEs) in tissues increases in DM. AGEs can modify the functional properties of intracellular proteins such as antioxidant enzymes, induce crosslinking of collagen leading to increased stiffness of the blood vessels, and interact with a receptor for AGEs (RAGE), which activate proinflammatory signaling pathways [6–8]. Therefore, AGEs are thought to play an important role in the pathogenesis of diabetic microangiopathy [9–11], particularly in the progression of DR [12,13]. However, the relevance between AGEs levels and DR stages and the clinical utility of skin autofluorescence (sAF) measurements are largely unknown.

In this article, we investigated the potential roles of AGEs during progression of DR. Since non-invasively measured sAF can easily estimate the levels of AGE accumulation, we examined the demographic differences and AGE scores measured by sAF in each DR stages and evaluated the clinical relevance of AGEs in patients with DM, especially those with proliferative diabetic retinopathy (PDR). We provided a novel approach to identify patients at risk for DR progression.

2. Materials and Methods

2.1. Subjects

The current study adhered to the tenets of the Declaration of Helsinki, and was approved by the institutional review boards of Matsue Red Cross Hospital and the Seirei Hamamatsu General Hospital. This study was conducted at the Matsue Red Cross Hospital (No. 303, issued on 21 September 2016), Iinan Hospital (No. 309, issued on 18 November 2016), and Seirei Hamamatsu General Hospital (No. 2198, issued on 20 July 2016). All participants gave written informed consent for inclusion in the study. All patient information was anonymized, and their identifiers were removed prior to analysis. All data were gathered by a non-blinded physician. Subjects were recruited consecutively at the outpatient clinics of the three hospitals.

We included 394 eyes of 394 Japanese subjects (172 men, 222 women; mean age ± standard deviation (SD), 68.4 ± 13.7 years), i.e., subjects with DM (n = 229) and non-diabetic controls (n = 165). In the patients with DM, if both eyes were eligible for inclusion in the study, the eye with the worse DR stage was included; if both eyes had the same stage, the eye with the worse BCVA was included; if both eyes had the same BCVA, the right eye was included. The control subjects were 20 years and older, had no history and clinical signs of DM, did not use glaucoma medications, and the previous highest IOP obtained by any type of tonometer was 20 mmHg or lower; the eyes with better BCVA were included in the analysis. Eyes with retinal diseases other than DR and those with glaucoma other than NVG were excluded from this study.

The subjects were interviewed about a history of DM, systemic hypertension, insulin use, and current smoking habits. In patients with DM, the most recent blood hemoglobin A1c (HbA1c) levels were collected during the chart reviews. The participants underwent examinations including measurement of the best-corrected visual acuity (BCVA), intraocular pressure (IOP) by Goldmann applanation tonometry (AT 900, Haag-Streit AG, Koeniz, Switzerland), slit-lamp microscopy (RO 5000, Rodenstock, Munich, Germany), gonioscopy using a two-mirror gonioscopy lens (Magna View Gonio, Ocular instruments, Washinton, DC, USA), fundoscopy using a non-contact lens (Super Field, Volk Optical, Mentor, USA), and fundus photograph images (Nonmyd WX, Kowa Company, Aichi, Japan). The lens status (phakia/pseudophakia) observed during slit-lamp examination and the previous highest IOPs measured by Goldmann applanation tonometry were obtained from the medical records.

The patients with DM were divided into groups based on those with no DR (NDR, n = 101) and DR (n = 128). DR included simple DR (SDR, n = 36), pre-proliferative DR (PPDR, n = 25), and PDR (n = 67). PDR was further divided into those with (n = 22) and without (n = 45) neovascular glaucoma (NVG). The DR stages were diagnosed based on bilateral funduscopic findings using the Davis classification of DR, specifically, the presence of retinal dot hemorrhages and hard exudations are signs of SDR;
that of soft exudations, venous beading, and intraretinal microvascular abnormalities are signs of PPDR; and that of retinal neovascularization and vitreous or preretinal hemorrhages are signs of PDR [14]. NVG was diagnosed based on elevated IOP above 21 mmHg measured by Goldmann applanation tonometry and neovascularization of the iris and of the angle detected by slit lamp and gonioscopic examinations.

2.2. Measurement of AGEs in the Fingertip Skin

To estimate the AGEs, the participants underwent measurements of the sAF levels using the AGEs Sensor (Air Water Biodesign Inc., Kobe, Japan). The sAF levels were measured using the middle finger of the non-dominant hand in which the least skin melanin is present [15]. During the measurement, the fingertip was mildly compressed at the distal portion of the distal interphalangeal joint, which is the suitable region to avoid the non-specific sAF [16]. The sAF values were obtained with the excitation and emission wavelengths of 365 nm and 440 nm, respectively, which were correlated positively with the level of the hyperglycemia-associated AGEs, Nδ-(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine [16]. As we previously reported, the accuracy and usability of the AGEs Sensor was shown in the clinical settings [17]. The validation check process was carried out before each measuring time using an equipped fluorophore plate in the AGEs Sensor. The measurements of sAF were carried out consequently three times in each patient at the first visit, and the mean values were applied to the analyses. Trained examiners performed all measurements. Since the AGEs Sensor cannot measure accurately whether the finger to be measured has dirt on the surface of the skin, an injury, or a large amount of oil such as hand cream, removal of any dirt was conducted by using alcohol cotton. The measured AGEs were expressed as the AGE scores in arbitrary units with an upper limit of 10.0 and a lower limit of 0.0, and 0.5. An arbitrary unit approximately corresponds to the average scores of healthy Japanese subjects aged 50 years according to a recent manufacturer survey. The AGEs Sensor displays the value when the coefficient of variation reaches less than 1%. Based on our pilot study, the coefficient of variation and intraclass correlation coefficient (Cronbach’s α) of three repeated AGE measurements were 6.7 ± 7.3% and 0.938, respectively.

2.3. Statistical Analysis

To compare the two groups, the differences in the continuous data, i.e., age, BCVA, HbA1c, highest IOP, and AGE scores, were calculated using the unpaired Student t-test, and the differences in the categorical data, i.e., sex, lens status, presence of hypertension, insulin use, current smoking habit, and DR, were calculated using Fisher’s exact probability test. For comparisons among the three study groups, we performed one-way analysis of variance followed by post-hoc unpaired t-tests for continuous data and the G-test followed by the post-hoc Fisher’s exact probability test for categorical data. P values of 0.0167 and 0.0033 for the unpaired t-tests or Fisher’s exact probability test were considered significant levels at 5% and 1%, respectively, based on the Bonferroni correction. To determine the independent factors associated with the AGE score, we also performed multivariate logistic regression analyses with the quartiles of the AGE scores as the response variables and with the covariates of age, sex, lens status, BCVA, highest IOP, presence of hypertension, DR, and current smoking habit. All statistical analyses were calculated using the JMP Pro statistical software version 14.2 (SAS Institute, Inc., Cary, NC, USA). All reported p values are two-sided. The data are expressed as the means ± SD for continuous variables and as numbers and percentages for categorical variables. For the statistical analyses, the decimal BCVA was converted into the logarithm of the minimum angle of resolution (logMAR). Counting fingers, hand motions, light perception, and no light perception were regarded as decimal VAs of 0.0025, 0.002, 0.0016, and 0.0013, respectively [18].

3. Results

The demographic subject data, including age, sex, presence of hypertension, current smoking habit, insulin use, HbA1c, lens status, BCVA, highest IOP, and AGE scores, are shown in Table 1.
All parameters differed significantly between the control and DM groups \((p < 0.01)\), and all parameters except for hypertension were statistically significant among control, NDR, and DR groups \((p < 0.05)\).

Compared to the control group \((0.52 \pm 0.12)\), the AGE scores were significantly higher in the DM \((0.59 \pm 0.17, p < 0.0001)\), NDR \((0.58 \pm 0.16, p = 0.0012)\), and DR \((0.60 \pm 0.18, p < 0.0001)\) groups.

| Parameters | Control (N=165) | DM (N=229) | p-Value * | NDR (N=101) | DR (N=128) | p-Value b |
|------------|----------------|-------------|-----------|-------------|------------|-----------|
| N          | 165            | 229         |           | 101         | 128        |           |
| Age (years) Mean ± SD range | 70.9 ± 14.1 | 66.6 ± 13.0 | 0.0017 ** | 68.0 ± 14.6 | 65.5 ± 11.6 | 0.0028 ** |
| Sex        |                |             |           |             |            |           |
| Men, n (%)  | 47 (28.5)      | 125 (54.6)  | <0.0001 ** | 49 (48.5)   | 76 (59.4)  | <0.0001 ** |
| Women, n (%)| 118 (71.5)     | 104 (45.4)  |           | 52 (51.5)   | 52 (40.6)  |           |
| Hypertension No, n (%) | 94 (57.0) | 105 (45.9) | 0.0323 * | 49 (48.5)  | 56 (43.8)  | 0.0723    |
| Yes, n (%)  | 71 (43.0)      | 124 (54.1)  |           | 52 (51.5)   | 72 (56.2)  |           |
| Mean ± SD range | –         | 7.8 ± 0.1   |           | 8.1 ± 2.7   | 7.6 ± 1.8  |           |
| Insulin usage No, n (%) | –         | 144 (63.7)  |           | 71 (72.4)   | 73 (57.0)  |           |
| Yes, n (%)  | 82 (36.3)      |            |           | 27 (27.6)   | 55 (43.0)  |           |
| Current smoking habit No, n (%) | 153 (92.7) | 189 (82.9) | 0.0039 ** | 82 (81.2)  | 107 (84.2) | 0.0132 *  |
| Yes, n (%)  | 12 (7.3)       | 39 (17.1)   |           | 19 (18.8)   | 20 (15.8)  |           |
| Lens status Phakic, n (%) | 132 (80.0) | 143 (62.5) | 0.0002 ** | 79 (78.2)  | 64 (50.0)  | <0.0001 ** |
| Pseudophakic, n (%) | 33 (20.0) | 87 (37.5)  |           | 22 (21.8)   | 64 (50.0)  |           |
| BCVA (LogMAR) Mean ± SD range | 0.12 ± 0.22 | 0.34 ± 0.65 | <0.0001 ** | 0.10 ± 0.27 | 0.53 ± 0.78 | <0.0001 ** |
| Highest IOP (mmHg) Mean ± SD range | 14.3 ± 2.8 | 19.2 ± 9.5 | <0.0001 ** | 16.5 ± 4.3 | 21.4 ± 11.7 | <0.0001 ** |
| AGEs score (A.U.) Mean ± SD range | 0.52 ± 0.12 | 0.59 ± 0.17 | <0.0001 ** | 0.58 ± 0.16 | 0.60 ± 0.18 | <0.0001 ** |

\* Comparison between control and DM groups by using unpaired Student t-test for continuous data and by using Fisher’s exact probability test for categorical data. * and ** correspond to the significance levels at 5% \((p < 0.05)\) and 1% \((p < 0.01)\), respectively. 

\* Comparison among control, NDR, and DR groups by using one-way ANOVA for continuous data and by using G-test for categorical data. 

\* Comparison between either pair of control, NDR, or DR groups by using post-hoc unpaired Student t-test for continuous data and by using Fisher’s exact probability test for categorical data. # and ## correspond to the significance levels at 5% \((p < 0.0167)\) and 1% \((p < 0.0033)\), respectively, by Bonferroni correction for multiple comparisons. One apheric case is included in pseudophakic cases. 

N, number of participants; SD, standard deviation; DM, diabetes mellitus; NDR, no diabetic retinopathy; DR, diabetic retinopathy; Glycated Hemoglobin A1c; BCVA, best-corrected visual acuity; IOP, intraocular pressure; AGEs, advanced glycation end products; A.U., arbitrary unit. 

Table 2 shows the comparisons of groups stratified by quartiles of AGE scores. Significant differences were seen in the age, sex, DR, lens status, and highest IOP among the four quartiles \((p < 0.05)\), and only the highest quartile (Q4) showed statistical significance compared with the Q1 and/or Q2 quartiles in post-hoc comparisons \((p < 0.0083)\). The proportion of patients with PDR was significantly higher in the Q4 group than other quartiles \((p < 0.0001)\).
Table 2. Demographic subject data stratified by quartiles of AGE scores.

| Parameters                      | Q1               | Q2               | Q3               | Q4               | p-Value * |
|--------------------------------|------------------|------------------|------------------|------------------|-----------|
| Range                           | N                | N                | N                | N                |           |
| Age (years)                     |                  |                  |                  |                  |           |
| Mean ± SD                       | 71.4 ± 12.3      | 68.1 ± 12.9      | 68.5 ± 13.8      | 65.5 ± 15.0      | 0.0259    |
| p-value, vs. Q1 b                | –                | 0.0903           | 0.1271           | 0.0024           |           |
| p-value, vs. Q2 b                | –                | –                | 0.8571           | 1.851            |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.1296           |           |
| Sex                             |                  |                  |                  |                  |           |
| Men, n (%)                      | 34 (33.7)        | 40 (41.4)        | 41 (41.4)        | 57 (59.2)        | 0.0011    |
| Women, n (%)                    | 67 (66.3)        | 56 (58.3)        | 58 (58.6)        | 41 (41.8)        |           |
| p-value, vs. Q1 b                | –                | 0.3030           | 0.3069           | 0.0006           |           |
| p-value, vs. Q2 b                | –                | –                | 1.0000           | 0.0310           |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.0227           |           |
| Hypertension                    |                  |                  |                  |                  |           |
| No, n (%)                       | 52 (51.5)        | 55 (57.3)        | 50 (50.5)        | 42 (42.9)        | 0.1647    |
| Yes, n (%)                      | 49 (48.5)        | 41 (42.7)        | 49 (49.5)        | 56 (57.1)        |           |
| p-value, vs. Q1 b                | –                | 0.3030           | 0.3069           | 0.0006           |           |
| p-value, vs. Q2 b                | –                | –                | 1.0000           | 0.0310           |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.0227           |           |
| Diabetic retinopathy            |                  |                  |                  |                  |           |
| No, n (%)                       | 55 (54.5)        | 45 (46.9)        | 47 (47.5)        | 18 (18.4)        | <0.0001   |
| Yes, n (%)                      | 60 (58.3)        | 24 (24.0)        | 24 (24.2)        | 30 (30.6)        |           |
| p-value, vs. Q1 b                | –                | 0.3030           | 0.3069           | 0.0006           |           |
| p-value, vs. Q2 b                | –                | –                | 1.0000           | 0.0310           |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.0227           |           |
| Insulin use                     |                  |                  |                  |                  |           |
| No, n (%)                       | 30 (66.7)        | 38 (74.5)        | 33 (66.0)        | 43 (53.8)        | 0.0530    |
| Yes, n (%)                      | 15 (33.3)        | 13 (25.5)        | 17 (34.0)        | 37 (46.3)        |           |
| p-value, vs. Q1 b                | –                | 0.3030           | 0.3069           | 0.0006           |           |
| p-value, vs. Q2 b                | –                | –                | 1.0000           | 0.0310           |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.0227           |           |
| Current smoking habit           |                  |                  |                  |                  |           |
| No, n (%)                       | 86 (85.1)        | 82 (86.3)        | 90 (90.9)        | 84 (85.7)        | 0.6899    |
| Yes, n (%)                      | 15 (14.9)        | 13 (13.7)        | 9 (9.1)          | 14 (14.3)        |           |
| Lens status                     |                  |                  |                  |                  |           |
| Phakic, n (%)                   | 76 (75.3)        | 70 (72.9)        | 72 (72.7)        | 58 (59.2)        | 0.0213    |
| Pseudophakic, n (%)             | 5 (56.8)         | 26 (27.1)        | 27 (27.3)        | 40 (40.9)        |           |
| p-value, vs. Q1 b                | –                | 0.7466           | 0.7480           | 0.0230           |           |
| p-value, vs. Q2 b                | –                | –                | 1.0000           | 0.0496           |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.0513           |           |
| BCVA (logMAR)                   |                  |                  |                  |                  |           |
| Mean ± SD                       | 0.19 ± 0.39      | 0.23 ± 0.47      | 0.23 ± 0.54      | 0.33 ± 0.66      | 0.3040    |
| p-value, vs. Q1 b                | –                | –                | –                | 0.08-2.89        |           |
| p-value, vs. Q2 b                | –                | –                | –                | 0.08-2.89        |           |
| p-value, vs. Q3 b                | –                | –                | –                | 0.08-2.89        |           |
| p-value, vs. Q4 b                | –                | –                | –                | 0.08-2.89        |           |

* Comparison of characteristics stratified by the quartiles of the AGE scores using one-way analysis of variance for continuous data and using the exact Cochran-Armitage trend test or G-test for categorical data. * and ** correspond to the significance levels at 5% (p < 0.05) and 1% (p < 0.01), respectively. b Comparison between either pair of Q1-4 groups using the post-hoc unpaired Student t-test for continuous data and using Fisher’s exact probability test for categorical data. # and ## correspond to the significance levels at 5% (p < 0.0083) and 1% (p < 0.0016), respectively, using the Bonferroni correction for multiple comparisons. One aphakic case is included among the pseudophakic cases. Q, quartile; N, number of participants; SD, standard deviation; NDR, no diabetic retinopathy; SDR, simple diabetic retinopathy; PPDR, pre-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; HbA1c, glycated hemoglobin A1c; BCVA, best-corrected visual acuity; IOP, intraocular pressure; logMAR, logarithm of the minimum angle of resolution.

The results of the comparison by multivariate logistic regression analysis of the Q1 and the Q2-Q4 groups are shown in Table 3. Multivariate analysis, which included age, sex, lens status, BCVA, highest IOP, presence of hypertension, DR, and current smoking habit, indicated that female gender (/men, OR = 0.38; p = 0.0059) and presence of DR = 0.0009, PDR (/control, OR = 6.73), non-PDR (/control, OR = 3.09) and PDR (/non-PDR, OR = 2.18) were independent variables significantly associated with
the AGE score when compared to Q4 to Q1 as references. The results suggested that men and the presence of DM and DR were associated with the AGE score with the highest quartile. We also evaluated the association between AGES scores and DR stages in male and female patients separately, which demonstrated statistically significant relevance between AGES scores and DR grades only in female patients (Supplementary Table S1).

Table 3. Multivariate logistic regression analysis for comparisons among quartile AGES groups.

| Parameters                              | Q1                      | Q2                      | Q3                      | Q4                      |
|-----------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Entire model                            | —                       | 0.0001 **               | 0.0005 **               | <0.0001 **              |
| Age (/year)                             | —                       | 0.0981                  | 0.1670                  | 0.0540                  |
| OR (95% CI)                             | 1                       | 0.98 (0.95–1.00)        | 0.98 (0.96–1.01)        | 1.03 (0.99–1.05)        |
| Women (/men)                            | —                       | 0.2552                  | 0.1668                  | 0.0059 **               |
| OR (95% CI) women/men                   | 1                       | 0.68 (0.35–1.32)        | 0.62 (0.33–1.21)        | 0.38 (0.20–0.76) **     |
| Hypertension, yes (/no)                 | —                       | 0.6611                  | 0.5677                  | 0.1388                  |
| OR (95% CI)                             | 1                       | 0.87 (0.48–1.59)        | 1.19 (0.64–2.24)        | 1.64 (0.85–3.18)        |
| DR, yes (/no)                           | —                       | 0.9521                  | 0.9547                  | 0.0009 **               |
| OR (95% CI) non-PDR/control             | 1.11 (0.58–2.11)        | 0.95 (0.45–2.00)        | 3.09 (1.48–6.44) **     |
| OR (95% CI) PDR/control                 | 1.08 (0.31–3.72)        | 1.10 (0.31–3.83)        | 6.73 (1.96–23.16) **    |
| OR (95% CI) PDR/controls                | 0.98 (0.30–3.16)        | 1.17 (0.35–3.92)        | 2.18 (0.68–6.96)        |
| Current smoking habit, yes/no           | —                       | 0.3262                  | 0.0198 *                | 0.1309                  |
| OR (95% CI)                             | 1                       | 0.64 (0.26–1.58)        | 0.29 (0.10–0.82) *      | 0.48 (0.18–1.25)        |
| Phakic (/pseudophakic)                  | —                       | 0.4538                  | 0.5659                  | 0.3425                  |
| BCVA (logMAR)                           | 1                       | 0.75 (0.36–1.56)        | 1.26 (0.57–2.77)        | 0.67 (0.29–1.53)        |
| P-value                                 | —                       | 0.5757                  | 0.4068                  | 0.7487                  |
| OR (95% CI)                             | 1                       | 1.24 (0.56–2.85)        | 0.70 (0.31–1.62)        | 0.67 (0.29–1.53)        |
| Highest IOP (mmHg)                      | —                       | 0.9206                  | 0.0097 **               | 0.6988                  |
| OR (95% CI)                             | 1                       | 1.00 (0.93–1.06)        | 1.09 (1.01–1.16) **     | 0.99 (0.93–1.05)        |

Data analysis was performed using multivariate logistic regression analysis to compare the Q1 and the Q2-4 groups. Independent variables considered for the model are those thought to be possibly biologically related to the AGE score. DR grades are classified into three groups including PDR, non-PDR (DM without PDR), and control. P-values were calculated using the likelihood ratio test. * and ** correspond to the significance levels at 5% (p < 0.05) and 1% (p < 0.01), respectively. To calculate the odds ratios, the Q1 group is the reference. Q, quartile; OR, odds ratio; CI, confidence interval; y, yes; n, no; DR, diabetic retinopathy; PDR, no diabetic retinopathy; BCVA, best-corrected visual acuity; IOP, intraocular pressure; OR, odds ratio.

Since the DR was associated with a higher AGE level, we further compared the AGE level between subjects with PDR and other DR subjects (Table 4). The comparisons of demographic data according to DR grades were shown in Supplementary Table S2. Compared to the DM without the PDR group, the PDR group was younger (p = 0.0009) and more pseudophakic (p < 0.0001) and had worse BCVA (p < 0.0001) and higher IOP (p < 0.0001). Compared to the non-PDR group (0.56 ± 0.15), the AGE scores were significantly higher in the PDR group (0.64 ± 0.02, p = 0.0015); the difference was significant in PDR without NVG (0.64 ± 0.19, p = 0.0059) but was borderline in the PDR with NVG (0.64 ± 0.23, p = 0.0426).
Finally, we assessed the risk factors for PDR using multivariate models (Table 5). The results showed that, age (/year, OR = 0.92, p < 0.001), female gender (/male gender, OR = 0.35, p = 0.0130), phakia (/ pseudophakia, OR = 0.88, p < 0.0001), BCVA (/logMAR, OR = 23.67, p < 0.0001), highest IOP (/mmHg, OR = 1.08, p = 0.0197), and AGE scores (/A.U., OR = 27.85, p = 0.0100) were associated significantly with PDR, although hypertension and current smoking were not. The results suggested that younger age, male gender, pseudophakia, worse VA, higher IOP, and higher AGEs scores were the risk factors for PDR.
Table 5. Multivariate logistic regression analysis for risk factors of PDR.

| Parameters                      | OR   | 95% CI      | p-Value * |
|---------------------------------|------|-------------|-----------|
| Entire model                    | —    | —           | <0.0001 **|
| Age (years)                     | 0.92 ** | 0.89–0.95 | <0.0001 **|
| Women (men)                     | 0.35 *      | 0.15–0.81   | 0.0130 *   |
| Hypertension, yes (no)          | 1.20 | 0.54–2.66   | 0.6629     |
| Current smoking habit, yes (no) | 0.48 | 0.13–1.79   | 0.2613     |
| Phakic (pseudophakic)           | 0.08 ** | 0.03–0.22 | <0.0001 **|
| BCVA (logMAR)                   | 23.67 ** | 7.40–75.75 | <0.0001 **|
| Highest IOP (mmHg)              | 1.08 *      | 1.01–1.16   | 0.0197 *   |
| AGE score (/A.U.)               | 27.85 *     | 2.69–288.30 | 0.0100 *   |

Multivariate logistic regression analysis was performed with the following factors: age, sex, hypertension, current smoking habit, lens status, VA, highest IOP, and AGE score. * and ** correspond to the significance levels at 5% (p < 0.05) and 1% (p < 0.01), respectively. OR, odds ratio; CI, confidence interval; y, yes; n, no; BCVA, best-corrected visual acuity; IOP, intraocular pressure; AGES, advanced glycation end products; A.U., arbitrary units; logMAR, logarithm of the minimum angle of = resolution; BCVA, best-corrected visual acuity.

4. Discussion

This study was designed to investigate the role of AGES in patients with DR. Overall, the results suggested two important clinical findings. First, AGE scores were higher in patients with DM, and independently associated with progression of DR. Second, the highest quartile of the AGE scores had a higher proportion of PDR than the other quartiles.

The current results showed that AGES were an independent factor for development of DR. In fact, the AGE scores were significantly higher in patients with DR and those with DM compared to the control group, and the higher AGE score was correlated with the progression of DR. In addition, AGES were an independent risk factor for PDR; multivariate analyses were performed to adjust for background characteristics. Previous reports have shown that sAF was well correlated with tissue accumulation of AGES, past glycemic control in patients with DM [13], and the severity of DR [19]. The results of our study were consistent with those of previous studies, and the evidence we report suggested that AGES would be a key exacerbating factor for the progression of DR.

One possible explanation for this is that AGES play an important role in the oxidative stress-induced apoptosis of the retinal capillary pericytes [20]. Several studies have elucidated that AGES can induce intrinsic signaling pathways mediated mainly through a receptor for AGES (RAGE) expressed on the membrane of pericytes, leading to apoptosis of pericytes [21–23]. Since pericytic function is the main regulator of the basement membrane at the blood retinal barrier [24], selective pericyte loss, induced by AGES-RAGE signaling pathways, leads to disruption of the blood retinal barrier and the following development of DR [25]. Therefore, it is biologically plausible that AGES contribute to the progression of DR.

The second clinical suggestion we provide here is that the highest quartile of the AGE scores was associated with a higher proportion of DR, especially PDR. Previous reports have shown a clear correlation between the prevalence of DR and serum hydroimidazolone levels, which is one of the most abundant AGES in vivo, and the highest levels of hydroimidazolone in patients with PDR [26]. This evidence is particularly consistent with the current results. It is important that only the highest quartile group had a significantly higher proportion of PDR. This observation suggested that the level of AGES might not be correlated linearly with the severity of the DR stages; AGES might have been physiologically significant in the development of PDR when the levels of AGES become markedly elevated.

A possible mechanism to explain this finding is that AGES can promote intraocular vascular proliferation and inflammatory response, mainly through production of vascular endothelial growth factor (VEGF) and proinflammatory cytokines such as interleukins and tumor necrosis factors [27–30].
Previous reports have shown that AGEs stimulate release of VEGF by pericytes and Müller cells \[28,31\], which is conventionally recognized as a key physiologic mechanism of ischemia-induced retinal neovascularization \[32\]. In addition, a number of studies have revealed that inflammation is a critical contributor for the development of PDR \[33\], and AGEs can initiate inflammatory process via RAGE-mediated NF-κB signaling pathways \[34\]. These evidences strongly support our hypothesis that accumulation of AGEs to markedly high levels (i.e., the top 25 percentile) would be deeply involved in the development of PDR.

It is important to emphasize that our research showed no statistically significant difference of AGEs score between PDR and NVG groups. The pathogenesis of NVG is a neovascularization associated with retinal ischemia and ocular inflammatory response, however the majority of cases are related to excess VEGF production following retinal ischemia \[35\]. Therefore, we hypothesized that ischemia-induced VEGF production would be a much stronger aggravating factor for the development of NVG than the inflammatory response via RAGE signaling pathways. In fact, a previous study reported that the VEGF concentration in the vitreous fluid from patients with active PDR was significantly higher than in patients without PDR \[36\]. Nevertheless, we did not evaluate the associations between VEGF concentration and AGEs levels, and this hypothesis needs further investigation.

It is also interesting to note that younger age, male gender, pseudophakia, worse VA, and higher IOP were associated significantly with PDR in this study. This finding appears to be partially consistent with previously reported results, which indicated the independent risk factors for PDR \[37,38\]. Interestingly, our research revealed that younger age and male gender were associated with higher AGEs scores. The difference of dietary AGEs might explain this observation \[39\]. In addition, we also showed that pseudophakia was a significant risk factor for PDR \[40,41\]; a possible hypothesis for this finding is that AGEs might have an important role in the pathogenesis of cataracts. A previous report suggested that this hypothesis showed that the serum AGEs in diabetic patients with cataracts were significantly higher than those in non-diabetic controls without cataracts \[42\]. The current study reported the baseline characteristics of patients with PDR, which could be informative to identify individuals at risk of the development of PDR.

The current study had some limitations that might affect the generalizability of our findings. The complete demographic data were unavailable, which creates a potential selection bias. We did not directly measure serum AGEs concentration, however the fluorescence intensity measured by the AGEs Sensor was well correlated to the serum AGEs concentrations, and the increase of fluorescence intensity was associated with the presence of diabetic microvascular complications \[16\]. In addition, the measurement of AGEs via sAF was affected by skin pigmentation, which leads to lower measurement accuracy \[15\]. Nevertheless, the fingertip skin-based measurement with the AGEs Sensor used in this study might compensate for this shortage \[17\]. Therefore, the non-invasive measurement of skin AGEs accumulation by the AGEs Sensor was thought to be a reasonable method for the current study. Despite these limitations, our study has many strengths, including the large sample size of individuals, non-invasive objective measurement of AGEs, and comprehensive assessments of patients’ clinical characteristics.

5. Conclusions

The current results suggested that AGE scores were higher in patients with DM and independently associated with the progression of DR. In addition, the highest quartile of AGE scores had a higher proportion of patients with DR, in particular PDR. This study highlights the clinical use of the AGE score as a non-invasive and reliable marker of patients at risk of sight-threatening DR. The current findings warrant further research to identify the optimal cut-off value of the AGE score for differentiating patients with a high risk of developing severe DR.

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/11/1100/s1. Supplementary Table S1. Association between AGEs score and diabetic retinopathy grades by gender. Supplementary Table S2. Demographic subject data according to diabetic retinopathy grades.
Author Contributions: Conceptualization, M.Y., Y.G., A.O., and M.T.; methodology, M.Y., Y.G., A.O., and M.T.; formal analysis, Y.T., M.Y., and M.T.; investigation, Y.T., M.Y., J.F., Y.M., and M.T.; data curation, Y.T., M.Y., J.F., Y.M., and M.T.; writing—original draft preparation, Y.T. and M.T.; writing—review and editing, M.Y., J.F., Y.M., Y.G., and A.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: M.Y. is a former employee of Sharp Life Science Corp. and Air Water Biodesign Inc. A.O. and M.T. were provided a prototypic AGEs Sensor from Sharp Life Science Corp. Other authors declare no conflict of interest. Sharp Life Science Corp. and Air Water Biodesign Inc. had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Jampol, L.M.; Glassman, A.R.; Sun, J. Evaluation and care of patients with diabetic retinopathy. *N. Engl. J. Med.* 2020, 382, 1629–1637. [CrossRef]
2. Cai, X.; Chen, Y.; Yang, W.; Gao, X.; Han, X.-Y.; Ji, L. The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: A meta-analysis. *Endocrine* 2018, 62, 299–306. [CrossRef]
3. Yau, J.W.; Rogers, S.L.; Kawasaki, R.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.-J.; Dekker, J.M.; Fletcher, A.; Grauslund, J.; et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care* 2012, 35, 556–564. [CrossRef]
4. Schreur, V.; Van Asten, F.; Ng, H.; Weeda, J.; Groenewoud, J.M.; Tack, C.J.; Hoynig, C.B.; De Jong, E.K.; Klaver, C.C.; Klevering, B.J. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. *Acta Ophthalmol.* 2018, 96, 459–464. [CrossRef]
5. Wat, N.; Wong, R.L.; Wong, I.Y. Associations between diabetic retinopathy and systemic risk factors. *Hong Kong Med. J.* 2016. [CrossRef]
6. Bejarano, E.; Taylor, A. Too sweet: Problems of protein glycation in the eye. *Exp. Eye Res.* 2019, 178, 255–262. [CrossRef]
7. Nowotny, K.; Jung, T.; Höhn, A.; Weber, D.; Grune, T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. *Biomolecules* 2015, 5, 194–222. [CrossRef]
8. Bierhaus, A.; Hofmann, M.; Ziegler, R.; Nawroth, P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. *Cardiovasc. Res.* 1998, 37, 586–600. [CrossRef]
9. Noordzij, M.J.; Mulder, D.J.; Oomen, P.H.N.; Brouwer, T.; Jager, J.; Cabezas, M.C.; Lefrandt, J.D.; Smit, A.J. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus—a multi-centre study. *Diabet. Med.* 2012, 29, 1556–1561. [CrossRef]
10. Tanaka, K.; Tani, Y.; Asai, J.; Nemoto, F.; Kusano, Y.; Suzuki, H.; Hayashi, Y.; Asahi, K.; Nakayama, M.; Miyata, T.; et al. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes. *Diabet. Med.* 2012, 29, 492–500. [CrossRef]
11. Gerrits, E.G.; Lutgers, H.L.; Kleefstra, N.; Graaft, R.; Groenier, K.H.; Smit, A.J.; Gans, R.O.; Bilo, H.J. Skin autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications. *Diabetes Care* 2008, 31, 517–521. [CrossRef]
12. Beisswenger, P.J.; Makita, Z.; Curphey, T.J.; Moore, L.L.; Jean, S.; Brinck-Johnsen, T.; Bucala, R.; Vlassara, H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. *Diabetes* 1995, 44, 824–829. [CrossRef] [PubMed]
13. Araszkiewicz, A.; Naskret, D.; Zozulinska-Ziolkiewicz, R.; Pilacinski, S.; Ursuksa, A.; Grzelka, A.; Wegner, M.; Wiersz-Wysocka, B. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. *Microvasc. Res.* 2015, 98, 62–67. [CrossRef]
14. Wilkinson, C.; Ferris, F.L.; E Klein, R.; Lee, P.P.; Agardh, C.D.; Davis, M.; Dills, D.; Kampaik, A.; Parajasegaram, R.; Verdaguer, J.T. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 2003, 110, 1677–1682. [CrossRef]
15. Koetsier, M.; Nur, E; Chunmao, H.; Lutgers, H.L.; Links, T.P.; Smit, A.J.; Rakhorst, G.; Graaft, R. Skin color independent assessment of aging using skin autofluorescence. *Opt. Express* 2010, 18, 14416–14429. [CrossRef]
16. Yamanaka, M.; Matsumura, T.; Ohno, R.-I.; Fujiwara, Y.; Shinagawa, M.; Sugawa, H.; Hatano, K.; Shirakawa, J.-I.; Kinoshita, H.; Ito, K.; et al. Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. *J. Clin. Biochem. Nutr.* 2016, 58, 135–140. [CrossRef]

17. Shirakami, T.; Yamanaka, M.; Fujihara, J.; Matsuoka, Y.; Gohto, Y.; Ohana, A.; Tanito, M. Advanced glycation end product accumulation in subjects with open-angle glaucoma with and without Exfoliation. *Antioxidants* 2020, 9, 755. [CrossRef]

18. Grover, S.; A Fishman, G.; Anderson, R.J.; Tozatti, M.S.; Heckenlively, J.R.; Weleber, R.G.; O Edwards, A.; Brown, J. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. *Ophthalmology* 1999, 106, 1780–1785. [CrossRef]

19. Hirano, T.; Iesato, Y.; Toriyama, Y.; Imai, A.; Chiba, D.; Murata, T. Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients. *J. Diabetes Complicat.* 2014, 28, 729–734. [CrossRef]

20. Santos, G.S.P.; Prazeres, P.H.D.M.; Mintz, A.; Birbair, A. Role of pericytes in the retina. *Eye* 2018, 32, 483–486. [CrossRef]

21. Chung, Y.-R.; Choi, J.A.; Koh, J.-Y.; Yoon, Y.H. Ursodeoxycholic acid attenuates endoplasmic reticulum stress-related retinal pericyte loss in streptozotocin-induced diabetic mice. *J. Diabetes Res.* 2017, 2017, 176392. [CrossRef]

22. Lin, W.-J.; Ma, X.-F.; Hao, M.; Zhou, H.-R.; Yu, X.-Y.; Shao, N.; Gao, X.-Y.; Kuang, H.-Y. Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products. *Peptides* 2018, 105, 7–13. [CrossRef]

23. Rangasamy, S.; Monickaraj, F.; Legendre, C.; Cabrera, A.P.; Llaci, L.; Bilagody, C.; McGuire, P.; Das, A. Transcriptomics analysis of pericytes from retinas of diabetic animals reveals novel genes and molecular pathways relevant to blood-retinal barrier alterations in diabetic retinopathy. *Exp. Eye Res.* 2020, 195, 108043. [CrossRef] [PubMed]

24. Park, D.Y.; Lee, J.; Kim, J.; Kim, K.; Hong, S.; Han, S.; Kubota, Y.; Augustin, H.G.; Ding, L.; Kim, J.W.; et al. Plastic roles of pericytes in the blood–retinal barrier. *Nat. Commun.* 2017, 8, 15296. [CrossRef]

25. Ogura, S.; Kurata, K.; Hattori, Y.; Takase, H.; Ishiguro-Oonuma, T.; Hwang, Y.; Ahn, S.; Park, I.; Ikeda, W.; Kusuahara, S.; et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. *JCI Insight* 2017, 2, e90905. [CrossRef]

26. Fosmark, D.S.; Torjesen, P.A.; Kilhovd, B.K.; Berg, T.J.; Sandvik, L.; Hanssen, K.F.; Agardh, C.-D.; Agardh, E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. *Metabolism* 2006, 55, 233–236. [CrossRef] [PubMed]

27. Chen, Y.-J.; Chan, D.-C.; Chiang, C.-K.; Wang, C.-C.; Yang, T.-H.; Lan, K.-C.; Chao, S.-C.; Tsai, K.-S.; Yang, R.-S.; Liu, S.-H. Advanced glycation end-products induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-κB pathway activation. *J. Orthop. Res.* 2015, 34, 791–800. [CrossRef]

28. Shimizu, F.; Sano, Y.; Haruki, H.; Kanda, T. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. *Diabetologia* 2011, 54, 1517–1526. [CrossRef] [PubMed]

29. Sun, L.; Huang, T.; Xu, W.; Sun, J.; Lv, Y.; Wang, Y. Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-Pi3K/AKT signaling pathway. *Sci. Rep.* 2017, 7, 1–12. [CrossRef]

30. Kandarakis, S.A.; Piperi, C.; Topouzis, F.; Papavassiliou, A.G. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. *Prog. Retin. Eye Res.* 2014, 42, 85–102. [CrossRef]
34. Xu, J.; Chen, L.-J.; Yu, J.; Wang, H.-J.; Zhang, F.; Liu, Q.; Wu, J. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. *Cell. Physiol. Biochem.* **2018**, *48*, 705–717. [CrossRef]
35. Sivak-Callcott, J.; O’Day, D.M.; Gass, J.M.; Tsai, J.C. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. *Ophthalmology* **2001**, *108*, 1767–1776. [CrossRef]
36. Aiello, L.M.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E.; et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N. Engl. J. Med.* **1994**, *331*, 1480–1487. [CrossRef]
37. Nittala, M.G.; Keane, P.A.; Zhang, K.; Sadda, S.R. Risk factors for proliferative diabetic retinopathy in a Latino American population. *Retina* **2014**, *34*, 1594–1599. [CrossRef]
38. Yasuda, M.; Shimura, M.; Kunikata, H.; Kanazawa, H.; Yasuda, K.; Tanaka, Y.; Konno, H.; Takahashi, M.; Kokubun, T.; Maruyama, K.; et al. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. *Curr. Eye Res.* **2015**, *40*, 338–345. [CrossRef]
39. Nowotny, K.; Schröter, D.; Schreiner, M.; Grune, T. Dietary advanced glycation end products and their relevance for human health. *Ageing Res. Rev.* **2018**, *47*, 55–66. [CrossRef]
40. Davis, M.D.; Fisher, M.R.; Gangnon, R.; Barton, F.; Aiello, L.M.; Chew, E.Y.; Ferris, F.L.; Knatterud, G.L. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. *Investig. Ophthalmol. Vis. Sci.* **1998**, *39*, 233–252.
41. Raman, R.; Rani, P.K.; Rachepalle, S.R.; Gnanamoorthy, P.; Uthra, S.; Kumaramanickavel, G.; Sharma, T. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. *Ophthalmology* **2009**, *116*, 311–318. [CrossRef]
42. Gul, A.; Rahman, M.A.; Salim, A.; Simjee, S.U. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. *J. Diabetes Complicat.* **2009**, *23*, 343–348. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).